Trump says he’s ‘strongly’ considering reclassifying pot via executive order

Trump says he’s ‘strongly’ considering reclassifying pot via executive order


Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden “to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC.

Win Mcnamee | Getty Images

Pot stocks failed to light up for a second day on Monday even after President Donald Trump confirmed he’s considering an executive order loosening regulations on marijuana.

The Amplify Seymour Cannabis ETF (CNBS) took a leg up in afternoon trading after Trump said he was weighing reclassifying the drug. Still, the fund was down nearly 7% with investors taking profits following a surge of more than 50% on Friday.

When asked Monday if he was looking at an executive order on rescheduling weed, Trump responded “We are considering that.”

“A lot of people want to see it the reclassification, because it leads to tremendous amounts of research that can’t be done unless you reclassify,” he said. “So we are looking at that very strongly.”

Trump’s comment comes after reports on Friday said the president was thinking about instructing federal agencies to reclassify marijuana as a less-regulated Schedule III drug from a Schedule I substance. A person familiar with the matter told CNBC an order from the White House could come as soon as Monday.

The reports ignited a rally in the sector on Friday that drove the Amplify Seymour fund to its best day on record. The ETF swung into positive territory for the year, putting it on track to snap a four-year losing streak.

Industry insiders have long expected this change in classification, which would move cannabis out of a group of drugs that includes heroin to a cohort alongside steroids and Tylenol with codeine. Trump floated a change in marijuana’s classification in August.

But they said there’s more optimism that enough momentum exists to get such a move — which could help warm up banks and big investors to the sector — across the finish line.

“I’m a lot more optimistic than I ever have been,” Tilray CEO Irwin Simon told CNBC on Friday.

Weed producers Tilray Brands and Canopy Growth slid 10% and 4.6%, respectively, in Monday’s session. Retailer SNDL tumbled more than 13%.

— CNBC’s Kevin Breuninger and Brandon Gomez contributed reporting.

Get Morning Squawk directly to your inbox



Source

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More
Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More